Pharmatest underlines radiotherapy expertise

Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services has underlined its expertise in working with radioactive compounds after publishing results of latest collaboration with life sciences giant Bayer.

Inhibiting prostate cancer growth

A Recent scientific publication of Pharmatest in collaboration with Bayer details success in testing efficacy of radiotherapies in preclinical oncology models. The work was published in August 2017 in the journal Clinical Cancer Research, demonstrating efficacy of radium-223 dichloride (Xofigo) to inhibit prostate cancer growth in bone microenvironment. The efficacy of Xofigo has been confirmed in clinical studies and Xofigo is currently in use in castration-resistant prostate cancer patients with advanced bone metastatic disease.

The study continues a long-established collaboration in the radiotherapy field between Bayer and Pharmatest.

Radiotherapy testing leader

Pharmatest has almost a decade of experience in testing efficacy of radioactive compounds in preclinical efficacy models, which has generated many scientific publications, including published papers in scientific journals and oral and poster presentations in leading scientific events.

Jussi Halleen, CEO of Pharmatest commented: “I am proud of the strong expertise of Pharmatest in testing efficacy of radiotherapies in preclinical studies. Setting up the capacity, training the personnel and obtaining the required licenses in compliance with relevant legislation has required much effort over the years but this has paid off in firmly establishing Pharmatest among the global leaders in the field.”

Pharmatest Services offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology, Pharmatest has strong expertise in bone metastasis models.

About Pharmatest

Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.